{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T05:29:55Z","timestamp":1792214995901,"version":"4.4.0"},"reference-count":102,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T00:00:00Z","timestamp":1740787200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100005765","name":"Universidade de Lisboa","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100005765","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Dig Dis Sci"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1007\/s10620-025-08912-4","type":"journal-article","created":{"date-parts":[[2025,3,1]],"date-time":"2025-03-01T16:31:54Z","timestamp":1740846714000},"page":"1746-1756","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Role of Alcohol in Steatotic Liver Disease: Impact on Patients with Cardiometabolic Risk Factors"],"prefix":"10.1007","volume":"70","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9403-1796","authenticated-orcid":false,"given":"Francisco","family":"Capinha","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6120-2333","authenticated-orcid":false,"given":"Sofia","family":"Carvalhana","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8537-8744","authenticated-orcid":false,"given":"Helena","family":"Cortez-Pinto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,3,1]]},"reference":[{"key":"8912_CR1","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1016\/j.jhep.2023.03.017","volume":"79","author":"H Devarbhavi","year":"2023","unstructured":"Devarbhavi H, Asrani SK, Arab JP et al. Global burden of liver disease: 2023 update. J. Hepatol. 2023;79:516\u2013537. https:\/\/doi.org\/10.1016\/j.jhep.2023.03.017.","journal-title":"J. Hepatol."},{"key":"8912_CR2","doi-asserted-by":"publisher","first-page":"1542","DOI":"10.1016\/j.jhep.2023.06.003","volume":"79","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Lazarus JV, Ratziu V et al. A multisociety Delphi consensus statement on new fatty liver disease nomenclature. J. Hepatol. 2023;79:1542\u20131556. https:\/\/doi.org\/10.1016\/j.jhep.2023.06.003.","journal-title":"J. Hepatol."},{"key":"8912_CR3","doi-asserted-by":"publisher","first-page":"e76","DOI":"10.1016\/j.jhep.2023.08.026","volume":"80","author":"H Hagstr\u00f6m","year":"2024","unstructured":"Hagstr\u00f6m H, Vessby J, Ekstedt M, Shang Y. 99% of patients with NAFLD meet MASLD criteria and natural history is therefore identical. J. Hepatol. 2024;80:e76\u2013e77. https:\/\/doi.org\/10.1016\/j.jhep.2023.08.026.","journal-title":"J. Hepatol."},{"key":"8912_CR4","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000604","author":"B Lee","year":"2023","unstructured":"Lee B, Dodge J, Terrault N. National prevalence estimates for steatotic liver disease and Sub-Classifications using consensus nomenclature. Hepatology. 2023. https:\/\/doi.org\/10.1097\/HEP.0000000000000604.","journal-title":"Hepatology"},{"key":"8912_CR5","doi-asserted-by":"publisher","first-page":"e54","DOI":"10.1016\/j.jhep.2023.07.021","volume":"80","author":"SJ Song","year":"2024","unstructured":"Song SJ, Lai JCT, Wong GL et al. Can we use old NAFLD data under the new MASLD definition? J. Hepatol. 2024;80:e54\u2013e56. https:\/\/doi.org\/10.1016\/j.jhep.2023.07.021.","journal-title":"J. Hepatol."},{"key":"8912_CR6","doi-asserted-by":"publisher","DOI":"10.1111\/apt.17958","author":"C Schneider","year":"2024","unstructured":"Schneider C, Schneider KM, Raptis A, Huang H, Trautwein C, Loomba R. Prevalence of at-risk MASH, MetALD and alcohol-associated steatotic liver disease in the general population. Aliment. Pharmacol. Ther. 2024. https:\/\/doi.org\/10.1111\/apt.17958.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"8912_CR7","doi-asserted-by":"publisher","first-page":"1393","DOI":"10.1097\/HEP.0000000000000664","volume":"79","author":"CM Lee","year":"2024","unstructured":"Lee CM, Yoon EL, Kim M et al. Prevalence, distribution, and hepatic fibrosis burden of the different subtypes of steatotic liver disease in primary care settings. Hepatology 2024;79:1393\u20131400. https:\/\/doi.org\/10.1097\/HEP.0000000000000664.","journal-title":"Hepatology"},{"key":"8912_CR8","doi-asserted-by":"publisher","first-page":"101127","DOI":"10.1016\/j.jhepr.2024.101127","volume":"6","author":"P Sripongpun","year":"2024","unstructured":"Sripongpun P, Kaewdech A, Udompap P, Kim WR. Characteristics and long-term mortality of individuals with MASLD, MetALD, and ALD, and the utility of SAFE score. JHEP Reports 2024;6:101127. https:\/\/doi.org\/10.1016\/j.jhepr.2024.101127.","journal-title":"JHEP Reports"},{"key":"8912_CR9","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2023.11.003","author":"M Kalligeros","year":"2023","unstructured":"Kalligeros M, Vassilopoulos A, Vassilopoulos S, Victor D, Mylonakis E, Noureddin M. Prevalence of steatotic liver disease (MASLD, MetALD and ALD) in the United States: NHANES 2017\u20132020. Clinical Gastroenterology and Hepatology. 2023. https:\/\/doi.org\/10.1016\/j.cgh.2023.11.003.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8912_CR10","doi-asserted-by":"publisher","first-page":"2929","DOI":"10.1111\/liv.16034","volume":"44","author":"E Petrie","year":"2024","unstructured":"Petrie E, Gray M, Bril F. Metabolic characteristics of patients with MetALD: Caveats of a new definition. Liver International\u202f: Official Journal of the International Association for the Study of the Liver 2024;44:2929\u20132938. https:\/\/doi.org\/10.1111\/liv.16034.","journal-title":"Liver International : Official Journal of the International Association for the Study of the Liver"},{"key":"8912_CR11","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S2468-1253(23)00443-0","volume":"9","author":"M Israelsen","year":"2024","unstructured":"Israelsen M, Torp N, Johansen S et al. Validation of the new nomenclature of steatotic liver disease in patients with a history of excessive alcohol intake: an analysis of data from a prospective cohort study. Lancet Gastroenterol. Hepatol. 2024;9:218\u2013228. https:\/\/doi.org\/10.1016\/S2468-1253(23)00443-0.","journal-title":"Lancet Gastroenterol. Hepatol."},{"key":"8912_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2024.04.031","author":"EASL Easd EASO","year":"2024","unstructured":"EASL Easd EASO. Clinical Practice Guidelines EASL \u2013 EASD \u2013 EASO Clinical Practice Guidelines on the management of metabolic dysfunction-associated steatotic liver disease (MASLD) q. J. Hepatol. 2024. https:\/\/doi.org\/10.1016\/j.jhep.2024.04.031.","journal-title":"J. Hepatol."},{"key":"8912_CR13","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1016\/j.jhep.2024.06.036","volume":"81","author":"D Marti-Aguado","year":"2024","unstructured":"Marti-Aguado D, Calleja JL, Vilar-Gomez E et al. Low-to-moderate alcohol consumption is associated with increased fibrosis in individuals with metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology 2024;81:930\u2013940. https:\/\/doi.org\/10.1016\/j.jhep.2024.06.036.","journal-title":"Journal of Hepatology"},{"key":"8912_CR14","doi-asserted-by":"publisher","first-page":"2045","DOI":"10.1136\/gutjnl-2024-332917","volume":"73","author":"AH Yang","year":"2024","unstructured":"Yang AH, Tincopa MA, Tavaglione F et al. Prevalence of steatotic liver disease, advanced fibrosis and cirrhosis among community-dwelling overweight and obese individuals in the USA. Gut 2024;73:2045\u20132053. https:\/\/doi.org\/10.1136\/gutjnl-2024-332917.","journal-title":"Gut"},{"key":"8912_CR15","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.1002\/hep.29631","volume":"67","author":"F \u00c5berg","year":"2018","unstructured":"\u00c5berg F, Helenius-Hietala J, Puukka P, F\u00e4rkkil\u00e4 M, Jula A. Interaction between alcohol consumption and metabolic syndrome in predicting severe liver disease in the general population. Hepatology 2018;67:2141\u20132149. https:\/\/doi.org\/10.1002\/hep.29631.","journal-title":"Hepatology"},{"key":"8912_CR16","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1016\/S0025-6196(24)00530-5","volume":"55","author":"J Ludwig","year":"1980","unstructured":"Ludwig J, Viggiano TR, McGill DB, Oh BJ. \u201cNonalcoholic steatohepatitis: Mayo Clinic experience with a hitherto unnamed disease.\u201d Mayo Clin Proc. 1980;55:434\u2013438. https:\/\/doi.org\/10.1016\/S0025-6196(24)00530-5.","journal-title":"Mayo Clin Proc."},{"key":"8912_CR17","doi-asserted-by":"publisher","DOI":"10.1054\/clnu.1999.0047","author":"H Cortez-Pinto","year":"2000","unstructured":"Cortez-Pinto H, Camilo M, Baptista A, Oliveira A, Moura M. Non-alcoholic fatty liver: Another feature of the metabolic syndrome? Clin. Nutr. 2000. https:\/\/doi.org\/10.1054\/clnu.1999.0047.","journal-title":"Clin. Nutr."},{"key":"8912_CR18","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","volume":"77","author":"ZM Younossi","year":"2023","unstructured":"Younossi ZM, Golabi P, Paik JM, Henry A, Van Dongen C, Henry L. The global epidemiology of nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NASH): a systematic review. Hepatology 2023;77:1335\u20131347. https:\/\/doi.org\/10.1097\/HEP.0000000000000004.","journal-title":"Hepatology"},{"key":"8912_CR19","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431","author":"ZM Younossi","year":"2015","unstructured":"Younossi ZM, Koenig A, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of non-alcoholic fatty liver disease\u2014Meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2015. https:\/\/doi.org\/10.1002\/hep.28431.","journal-title":"Hepatology"},{"key":"8912_CR20","doi-asserted-by":"publisher","DOI":"10.1038\/d41586-023-00676-z","author":"S Sidik","year":"2023","unstructured":"Sidik S. Diabetes and obesity are rising globally\u2014but some nations are hit harder. Nature. 2023. https:\/\/doi.org\/10.1038\/d41586-023-00676-z.","journal-title":"Nature"},{"key":"8912_CR21","doi-asserted-by":"publisher","first-page":"718","DOI":"10.1016\/j.jhep.2018.05.011","volume":"69","author":"L Pimpin","year":"2018","unstructured":"Pimpin L, Cortez-Pinto H, Negro F et al. Burden of liver disease in Europe: Epidemiology and analysis of risk factors to identify prevention policies. Journal of Hepatology 2018;69:718\u2013735. https:\/\/doi.org\/10.1016\/j.jhep.2018.05.011.","journal-title":"Journal of Hepatology"},{"key":"8912_CR22","doi-asserted-by":"publisher","first-page":"1547","DOI":"10.1002\/hep.27368","volume":"61","author":"M Ekstedt","year":"2015","unstructured":"Ekstedt M, Hangstrom H, Nasr P et al. Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology 2015;61:1547\u20131554. https:\/\/doi.org\/10.1002\/hep.27368.","journal-title":"Hepatology"},{"key":"8912_CR23","doi-asserted-by":"publisher","first-page":"E168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"K-C Sung","year":"2023","unstructured":"Sung K-C, Yoo TK, Lee YL et al. Comparative associations of nonalcoholic fatty liver disease and metabolic dysfunction\u2013associated fatty liver disease with coronary artery calcifications: A cross-sectional and longitudinal cohort study. Arteriosclerosis, Thrombosis, and Vascular Biology 2023;42:E168\u2013E185. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"8912_CR24","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/S2468-1253(21)00308-3","volume":"6","author":"A Mantovani","year":"2021","unstructured":"Mantovani A, Csermely A, Petracca G et al. Non-alcoholic fatty liver disease and risk of fatal and non-fatal cardiovascular events: An updated systematic review and meta-analysis. Lancet Gastroenterology & Hepatology 2021;6:903\u2013913. https:\/\/doi.org\/10.1016\/S2468-1253(21)00308-3.","journal-title":"Lancet Gastroenterology & Hepatology"},{"key":"8912_CR25","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1016\/j.cgh.2022.04.014","volume":"21","author":"CH Ng","year":"2023","unstructured":"Ng CH, Lim WH, Lim GEH et al. Mortality outcomes by fibrosis stage in nonalcoholic fatty liver disease: A systematic review and meta-analysis. Clinical Gastroenterology and Hepatology 2023;21:931-939.e5. https:\/\/doi.org\/10.1016\/j.cgh.2022.04.014.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8912_CR26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/nrgastro.2017.109","volume":"15","author":"ZM Younossi","year":"2018","unstructured":"Younossi ZM, Anstee QM, Marietti M et al. Global burden of NAFLD and NASH: Trends, predictions, risk factors, and prevention. Nature Reviews Gastroenterology & Hepatology 2018;15:11\u201320. https:\/\/doi.org\/10.1038\/nrgastro.2017.109.","journal-title":"Nature Reviews Gastroenterology & Hepatology"},{"key":"8912_CR27","doi-asserted-by":"publisher","first-page":"E168","DOI":"10.1161\/ATV.0000000000000153","volume":"42","author":"P Barton Duell","year":"2022","unstructured":"Barton Duell P, Welty FK, Miller M et al. Nonalcoholic fatty liver disease and cardiovascular risk: A scientific statement from the American Heart Association. Arteriosclerosis, Thrombosis, and Vascular Biology 2022;42:E168\u2013E185. https:\/\/doi.org\/10.1161\/ATV.0000000000000153.","journal-title":"Arteriosclerosis, Thrombosis, and Vascular Biology"},{"key":"8912_CR28","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/S0140-6736(18)31310-2","volume":"392","author":"M Griswold","year":"2018","unstructured":"Griswold M, FullmanHawley NC et al. Alcohol use and burden for 195 countries and territories, 1990\u20132016: A systematic analysis for the Global Burden of Disease Study 2016. Lancet 2018;392:1015\u20131035. https:\/\/doi.org\/10.1016\/S0140-6736(18)31310-2.","journal-title":"Lancet"},{"key":"8912_CR29","unstructured":"World Health Organization. (2018). Global status report on alcohol and health 2018, vol. 65, no. 1."},{"key":"8912_CR30","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12889-023-15749-x","volume":"23","author":"X Niu","year":"2023","unstructured":"Niu X, Chu L, Xu Y et al. Global prevalence, incidence, and outcomes of alcohol-related liver diseases: A systematic review and meta-analysis. BMC Public Health 2023;23:1\u201321. https:\/\/doi.org\/10.1186\/s12889-023-15749-x.","journal-title":"BMC Public Health"},{"key":"8912_CR31","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1136\/gutjnl-2019-320446","volume":"70","author":"H Hagstr\u00f6m","year":"2021","unstructured":"Hagstr\u00f6m H, Thiele M, Roelstraete B, S\u00f6derling J, Ludvigsson JF. Mortality in biopsy-proven alcohol-related liver disease: A population-based nationwide cohort study of 3,453 patients. Gut 2021;70:170\u2013179. https:\/\/doi.org\/10.1136\/gutjnl-2019-320446.","journal-title":"Gut"},{"key":"8912_CR32","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.jhep.2014.12.005","volume":"62","author":"G Askgaard","year":"2015","unstructured":"Askgaard G, Gr\u00f8nb\u00e6k M, Kj\u00e6r MS, Tj\u00f8nneland A, Tolstrup JS. Alcohol drinking pattern and risk of alcoholic liver cirrhosis: A prospective cohort study. Journal of Hepatology 2015;62:1061\u20131067. https:\/\/doi.org\/10.1016\/j.jhep.2014.12.005.","journal-title":"Journal of Hepatology"},{"key":"8912_CR33","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-43064-x","author":"C Ding","year":"2023","unstructured":"Ding C, Fat LN, Britton A et al. Binge-pattern alcohol consumption and genetic risk as determinants of alcohol-related liver disease. Nature Communications. 2023. https:\/\/doi.org\/10.1038\/s41467-023-43064-x.","journal-title":"Nature Communications"},{"key":"8912_CR34","doi-asserted-by":"publisher","first-page":"42","DOI":"10.1111\/ijlh.12426","volume":"38","author":"A Fredrik \u00c5berg","year":"2016","unstructured":"Fredrik \u00c5berg A, Helenius-Hietala J, Puukka P et al. Binge drinking and the risk of liver events: A population-based cohort study. International Journal of Laboratory Hematology 2016;38:42\u201349. https:\/\/doi.org\/10.1111\/ijlh.12426.","journal-title":"International Journal of Laboratory Hematology"},{"key":"8912_CR35","doi-asserted-by":"publisher","first-page":"635","DOI":"10.1053\/jhep.2002.31782","volume":"35","author":"BAD Raynard Balian Fallik","year":"2002","unstructured":"Raynard Balian Fallik BAD et al. Risk factors of fibrosis in alcohol-induced liver disease. Hepatology 2002;35:635\u2013638. https:\/\/doi.org\/10.1053\/jhep.2002.31782.","journal-title":"Hepatology"},{"key":"8912_CR36","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1038\/ajg.2016.107","volume":"111","author":"T Deleuran","year":"2016","unstructured":"Deleuran T, Vilstrup H, Jepsen P. Decreasing mortality among Danish alcoholic cirrhosis patients: A nationwide cohort study. American Journal of Gastroenterology 2016;111:817\u2013822. https:\/\/doi.org\/10.1038\/ajg.2016.107.","journal-title":"American Journal of Gastroenterology"},{"key":"8912_CR37","doi-asserted-by":"publisher","DOI":"10.1097\/HC9.0000000000000279","author":"A Wester","year":"2023","unstructured":"Wester A, Shang Y, Stal P, Hagstrom H. Time trends in mortality and life expectancy in 22,658 patients hospitalized with alcohol-associated cirrhosis: A nationwide cohort study. Hepatology Communications. 2023. https:\/\/doi.org\/10.1097\/HC9.0000000000000279.","journal-title":"Hepatology Communications"},{"key":"8912_CR38","doi-asserted-by":"publisher","first-page":"453","DOI":"10.2131\/jts.32.453","volume":"32","author":"K Nagata","year":"2007","unstructured":"Nagata K, Suzuki H, Sakaguchi S. Common pathogenic mechanism in development and progression of liver injury caused by non-alcoholic steatohepatitis. Journal of Toxicology Sciences 2007;32:453\u2013468. https:\/\/doi.org\/10.2131\/jts.32.453.","journal-title":"Journal of Toxicology Sciences"},{"key":"8912_CR39","doi-asserted-by":"publisher","first-page":"30","DOI":"10.2133\/dmpk.dmpk-10-rv-087","volume":"26","author":"S Sakaguchi","year":"2013","unstructured":"Sakaguchi S, Takahashi S, Sasaki T et al. Progression of alcoholic and non-alcoholic steatohepatitis: Common metabolic aspects of the innate immune system and oxidative stress. Drug Metabolism and Pharmacokinetics 2013;26:30\u201346. https:\/\/doi.org\/10.2133\/dmpk.dmpk-10-rv-087.","journal-title":"Drug Metabolism and Pharmacokinetics"},{"key":"8912_CR40","doi-asserted-by":"publisher","first-page":"595","DOI":"10.3350\/cmh.2020.0086","volume":"26","author":"BG Mendes","year":"2020","unstructured":"Mendes BG, Schnabl B. From intestinal dysbiosis to alcohol-associated liver disease. Clinical and Molecular Hepatology 2020;26:595\u2013605. https:\/\/doi.org\/10.3350\/cmh.2020.0086.","journal-title":"Clinical and Molecular Hepatology"},{"key":"8912_CR41","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1055\/s-2007-979470","volume":"1","author":"PF Lalor","year":"2007","unstructured":"Lalor PF, Faint J, Aarbodem Y et al. The Role of Cytokines and Chemokines in the Development of Steatohepatitis. Seminars in Liver Disease 2007;1:173\u2013193. https:\/\/doi.org\/10.1055\/s-2007-979470.","journal-title":"Seminars in Liver Disease"},{"key":"8912_CR42","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1016\/S0016-5085(98)70599-2","volume":"114","author":"CP Day","year":"1998","unstructured":"Day CP, James OF. Steatohepatitis: A tale of two \u201cHits\u201d? Gastroenterology. 1998;114:842\u2013845. https:\/\/doi.org\/10.1016\/S0016-5085(98)70599-2.","journal-title":"Gastroenterology."},{"key":"8912_CR43","doi-asserted-by":"publisher","DOI":"10.2174\/1381612826666200122152417","author":"A Craciun","year":"2020","unstructured":"Craciun A, Lackner C, Cortez-Pinto H. Nonalcoholic fatty liver disease versus alcohol-related liver disease: Is it really so different? Current Pharmaceutical Design. 2020. https:\/\/doi.org\/10.2174\/1381612826666200122152417.","journal-title":"Current Pharmaceutical Design"},{"key":"8912_CR44","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12944-024-02031-1","volume":"23","author":"G Tarantino","year":"2024","unstructured":"Tarantino G, Citro V. What are the common downstream molecular events between alcoholic and nonalcoholic fatty liver? Lipids in Health and Disease 2024;23:1\u201318. https:\/\/doi.org\/10.1186\/s12944-024-02031-1.","journal-title":"Lipids in Health and Disease"},{"key":"8912_CR45","doi-asserted-by":"publisher","first-page":"197","DOI":"10.1016\/j.jhep.2005.09.002","volume":"44","author":"H Cortez-Pinto","year":"2006","unstructured":"Cortez-Pinto H, Moura MCD, Day CP. Non-alcoholic steatohepatitis: From cell biology to clinical practice. Journal of Hepatology 2006;44:197\u2013208. https:\/\/doi.org\/10.1016\/j.jhep.2005.09.002.","journal-title":"Journal of Hepatology"},{"key":"8912_CR46","doi-asserted-by":"publisher","DOI":"10.1097\/HEP.0000000000000935","author":"GW Marek","year":"2024","unstructured":"Marek GW, Malhi H. MetALD: Does it require a different therapeutic option? Hepatology. 2024. https:\/\/doi.org\/10.1097\/HEP.0000000000000935.","journal-title":"Hepatology"},{"key":"8912_CR47","first-page":"437","volume":"91","author":"W Winston Dunn","year":"2015","unstructured":"Winston Dunn W, Carithers RL. Diagnosis and treatment of chronic liver disease. American Family Physician 2015;91:437\u2013446.","journal-title":"American Family Physician"},{"key":"8912_CR48","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jhep.2012.03.024","volume":"23","author":"JBS Winston Dunn","year":"2012","unstructured":"Winston Dunn JBS, Sanyal AJ, Brunt EM, Unalp-Arida A, Donohue M, McCullough AJ. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with nonalcoholic fatty liver disease (NAFLD). Bone 2012;23:1\u20137. https:\/\/doi.org\/10.1016\/j.jhep.2012.03.024.","journal-title":"Bone"},{"key":"8912_CR49","doi-asserted-by":"publisher","first-page":"378","DOI":"10.1111\/j.1365-2036.2010.04520.x","volume":"33","author":"A Moriya","year":"2011","unstructured":"Moriya A, Iwasaki Y, Ohguchi S et al. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2011;33:378\u2013388. https:\/\/doi.org\/10.1111\/j.1365-2036.2010.04520.x.","journal-title":"Aliment. Pharmacol. Ther."},{"key":"8912_CR50","doi-asserted-by":"publisher","first-page":"530","DOI":"10.1136\/gutjnl-2013-305718","volume":"63","author":"S Sookoian","year":"2014","unstructured":"Sookoian S, Casta\u00f1o GO, Pirola CJ. Modest alcohol consumption decreases the risk of nonalcoholic fatty liver disease: A meta-analysis of 43,175 individuals. Gut 2014;63:530\u2013532. https:\/\/doi.org\/10.1136\/gutjnl-2013-305718.","journal-title":"Gut"},{"key":"8912_CR51","doi-asserted-by":"publisher","first-page":"2090","DOI":"10.1002\/hep.29055","volume":"65","author":"VH Ajmera","year":"2018","unstructured":"Ajmera VH, Terrault NA, Harrison SA. HHS Public Access. Hepatology 2018;65:2090\u20132099. https:\/\/doi.org\/10.1002\/hep.29055.","journal-title":"HHS Public Access. Hepatology"},{"key":"8912_CR52","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1136\/bmj.38831.503113.7C","volume":"332","author":"JH Tolstrup","year":"2006","unstructured":"Tolstrup JH, Jensen MK, Tj\u00f8nneland A, Overvad K, Mukamal KJ, Gr\u00f8nb\u00e6k M. Prospective study of alcohol drinking patterns and coronary heart disease in women and men. British Medical Journal 2006;332:1244\u20131247. https:\/\/doi.org\/10.1136\/bmj.38831.503113.7C.","journal-title":"British Medical Journal"},{"key":"8912_CR53","first-page":"474","volume":"21","author":"C Wharton","year":"2007","unstructured":"Wharton C, Harris C. Roles of drinking pattern and type of alcohol consumed in coronary heart disease in men: Commentary. American Journal of Health Promotion 2007;21:474\u2013475.","journal-title":"American Journal of Health Promotion"},{"key":"8912_CR54","doi-asserted-by":"publisher","DOI":"10.1053\/j.gastro.2024.02.032","author":"ME Rinella","year":"2023","unstructured":"Rinella ME, Neuschwander-Tetri BA, Siddiqui MS et al. AASLD Practice Guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023. https:\/\/doi.org\/10.1053\/j.gastro.2024.02.032.","journal-title":"Hepatology"},{"key":"8912_CR55","doi-asserted-by":"publisher","first-page":"1388","DOI":"10.1016\/j.jhep.2015.11.004","volume":"64","author":"G Marchesini","year":"2016","unstructured":"Marchesini G, Day CP, Dufour J-F et al. EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Journal of Hepatology 2016;64:1388\u20131402. https:\/\/doi.org\/10.1016\/j.jhep.2015.11.004.","journal-title":"Journal of Hepatology"},{"key":"8912_CR56","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1016\/j.jhep.2010.04.008","volume":"53","author":"GM Ratziu","year":"2010","unstructured":"Ratziu GM, Bellentani S, Cortez-Pinto H, Day C. A position statement on NAFLD\/NASH based on the EASL 2009 special conference. Journal of Hepatology 2010;53:372\u2013384. https:\/\/doi.org\/10.1016\/j.jhep.2010.04.008.","journal-title":"Journal of Hepatology"},{"key":"8912_CR57","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.14309\/ajg.0000000000000340","volume":"114","author":"M Roerecke","year":"2019","unstructured":"Roerecke M, Vafaei A, Hasan OSM et al. Alcohol Consumption and Risk of Liver Cirrhosis: A Systematic Review and Meta-Analysis. American Journal of Gastroenterology. 2019;114:1574\u20131586. https:\/\/doi.org\/10.14309\/ajg.0000000000000340.","journal-title":"American Journal of Gastroenterology."},{"key":"8912_CR58","doi-asserted-by":"publisher","first-page":"1625","DOI":"10.1016\/j.cgh.2018.11.033","volume":"17","author":"ZM Younossi","year":"2019","unstructured":"Younossi ZM, Stepanova M, Ong J et al. Effects of Alcohol Consumption and Metabolic Syndrome on Mortality in Patients With Nonalcoholic and Alcohol-Related Fatty Liver Disease. Clinical Gastroenterology and Hepatology 2019;17:1625-1633.e1. https:\/\/doi.org\/10.1016\/j.cgh.2018.11.033.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8912_CR59","doi-asserted-by":"publisher","first-page":"1156","DOI":"10.1053\/j.gastro.2024.02.032","volume":"166","author":"RJ Wong","year":"2024","unstructured":"Wong RJ, Yang Z, Cheung R et al. Impact of Longitudinal Alcohol Use Patterns on Long-Term Risk of Cirrhosis Among US Veterans With Steatotic Liver Disease. Gastroenterology 2024;166:1156-1165.e4. https:\/\/doi.org\/10.1053\/j.gastro.2024.02.032.","journal-title":"Gastroenterology"},{"key":"8912_CR60","doi-asserted-by":"publisher","DOI":"10.1016\/j.cgh.2024.01.006","author":"P Nasr","year":"2024","unstructured":"Nasr P, Wester A, Ekstedt M et al. Misclassified Alcohol-related Liver Disease is Common in Presumed Metabolic Dysfunction-associated Steatotic Liver Disease and Highly Increases Risk for Future Cirrhosis. Clinical Gastroenterology and Hepatology. 2024. https:\/\/doi.org\/10.1016\/j.cgh.2024.01.006.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8912_CR61","doi-asserted-by":"publisher","first-page":"S469","DOI":"10.1016\/S0168-8278(24)01448-X","volume":"80","author":"D Marti Aguado","year":"2024","unstructured":"Marti Aguado D, Calleja JL, Vilar-Gomez E et al. FRI-213 Low-to-moderate alcohol consumption is associated with increased fibrosis in subjects with metabolic dysfunction-associated steatotic liver disease. Journal of Hepatology 2024;80:S469. https:\/\/doi.org\/10.1016\/S0168-8278(24)01448-X.","journal-title":"Journal of Hepatology"},{"key":"8912_CR62","doi-asserted-by":"publisher","first-page":"102292","DOI":"10.1016\/j.eclinm.2023.102292","volume":"65","author":"JH Moon","year":"2023","unstructured":"Moon JH, Jeong S, Jang H, Koo BK, Kim W. Metabolic dysfunction-associated steatotic liver disease increases the risk of incident cardiovascular disease: A nationwide cohort study. eclinicalmedicine. 2023;65:102292. https:\/\/doi.org\/10.1016\/j.eclinm.2023.102292.","journal-title":"eclinicalmedicine."},{"key":"8912_CR63","first-page":"229","volume":"74","author":"F Bray","year":"2024","unstructured":"Bray F, Laversanne M, Sung H et al. Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2024;74:229\u2013263.","journal-title":"CA: A Cancer Journal for Clinicians."},{"key":"8912_CR64","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1016\/j.cgh.2019.07.060","volume":"46","author":"M-VK Yang","year":"2019","unstructured":"Yang M-VK, Friese MM. Contemporary epidemiology of chronic liver disease and cirrhosis. Physiology & Behavior 2019;46:248\u2013256. https:\/\/doi.org\/10.1016\/j.cgh.2019.07.060.","journal-title":"Physiology & Behavior"},{"key":"8912_CR65","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1002\/hep.29913","volume":"68","author":"JA Marrero","year":"2018","unstructured":"Marrero JA, Kilik LM, Sirin CB et al. Diagnosis, staging, and management of hepatocellular carcinoma: 2018 practice guidance by the American Association for the Study of Liver Diseases. Hepatology 2018;68:723\u2013750. https:\/\/doi.org\/10.1002\/hep.29913.","journal-title":"Hepatology"},{"key":"8912_CR66","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.jhep.2018.03.019","volume":"69","author":"PR Galle","year":"2018","unstructured":"Galle PR, Forner A, Llovet JM et al. EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. Journal of Hepatology 2018;69:182\u2013236. https:\/\/doi.org\/10.1016\/j.jhep.2018.03.019.","journal-title":"Journal of Hepatology"},{"key":"8912_CR67","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1111\/apt.14937","volume":"48","author":"JG Stine","year":"2018","unstructured":"Stine JG, Wentworth BJ, Zimmet A et al. Systematic review with meta-analysis: Risk of hepatocellular carcinoma in non-alcoholic steatohepatitis without cirrhosis compared to other liver diseases. Alimentary Pharmacology & Therapeutics 2018;48:696\u2013703. https:\/\/doi.org\/10.1111\/apt.14937.","journal-title":"Alimentary Pharmacology & Therapeutics"},{"key":"8912_CR68","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1002\/hep.31288","volume":"73","author":"KA McGlynn","year":"2021","unstructured":"McGlynn KA, Petrick JL, El-Serag HB. Epidemiology of hepatocellular carcinoma. Hepatology 2021;73:4\u201313. https:\/\/doi.org\/10.1002\/hep.31288.","journal-title":"Hepatology"},{"key":"8912_CR69","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1002\/cncr.24982","volume":"116","author":"MM Hassan","year":"2010","unstructured":"Hassan MM, Curley SA, Li D et al. Association of diabetes duration and diabetes treatment with the risk of hepatocellular carcinoma. Cancer 2010;116:1938\u20131946. https:\/\/doi.org\/10.1002\/cncr.24982.","journal-title":"Cancer"},{"key":"8912_CR70","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1136\/gut.2004.052167","volume":"54","author":"JA Davila","year":"2005","unstructured":"Davila JA, Morgan RO, Shaib Y, McGlynn KA, El-Serag HB. Diabetes increases the risk of hepatocellular carcinoma in the United States: A population-based case-control study. Gut 2005;54:533\u2013539. https:\/\/doi.org\/10.1136\/gut.2004.052167.","journal-title":"Gut"},{"key":"8912_CR71","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1093\/jnci\/89.4.327","volume":"89","author":"R Nelson","year":"1997","unstructured":"Nelson R, Persky V, Davis F, Becker E. Re: Excess risk of primary liver cancer in patients with diabetes mellitus. Journal of the National Cancer Institute 1997;89:327\u2013328. https:\/\/doi.org\/10.1093\/jnci\/89.4.327.","journal-title":"Journal of the National Cancer Institute"},{"key":"8912_CR72","doi-asserted-by":"publisher","first-page":"1182","DOI":"10.1038\/bjc.2013.25","volume":"108","author":"WP Koh","year":"2013","unstructured":"Koh WP, Wang R, Jin A, Yu MC, Yuan JM. Diabetes mellitus and risk of hepatocellular carcinoma: Findings from the Singapore Chinese Health Study. British Journal of Cancer 2013;108:1182\u20131188. https:\/\/doi.org\/10.1038\/bjc.2013.25.","journal-title":"British Journal of Cancer"},{"key":"8912_CR73","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1053\/j.gastro.2003.10.065","volume":"126","author":"HB El-Serag","year":"2004","unstructured":"El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460\u2013468. https:\/\/doi.org\/10.1053\/j.gastro.2003.10.065.","journal-title":"Gastroenterology"},{"key":"8912_CR74","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1016\/0959-8049(94)90254-2","volume":"30","author":"H M\u00f8ller","year":"1994","unstructured":"M\u00f8ller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: A Danish record-linkage study. European Journal of Cancer 1994;30:344\u2013350. https:\/\/doi.org\/10.1016\/0959-8049(94)90254-2.","journal-title":"European Journal of Cancer"},{"key":"8912_CR75","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/j.jhep.2004.10.005","volume":"42","author":"JA Marrero","year":"2005","unstructured":"Marrero JA, Fontana RJ, Fu S, Conjeevaram HS, Su GL, Lok AS. Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma. Journal of Hepatology 2005;42:218\u2013224. https:\/\/doi.org\/10.1016\/j.jhep.2004.10.005.","journal-title":"Journal of Hepatology"},{"key":"8912_CR76","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/annonc\/mdn565","volume":"20","author":"J Polesel","year":"2009","unstructured":"Polesel J, Zucchetto A, Montella M et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Ann. Oncol. 2009;20:353\u2013357. https:\/\/doi.org\/10.1093\/annonc\/mdn565.","journal-title":"Ann. Oncol."},{"key":"8912_CR77","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1093\/annonc\/mdn565","volume":"20","author":"J Polesel","year":"2009","unstructured":"Polesel J, Zucchetto A, Montella M et al. The impact of obesity and diabetes mellitus on the risk of hepatocellular carcinoma. Annals of Oncology 2009;20:353\u2013357. https:\/\/doi.org\/10.1093\/annonc\/mdn565.","journal-title":"Annals of Oncology"},{"key":"8912_CR78","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1093\/annonc\/mdu020","volume":"25","author":"F Turati","year":"2014","unstructured":"Turati F, Galeone F, Rota M et al. Alcohol and liver cancer: A systematic review and meta-analysis of prospective studies. Annals of Oncology 2014;25:1526\u20131535. https:\/\/doi.org\/10.1093\/annonc\/mdu020.","journal-title":"Annals of Oncology"},{"key":"8912_CR79","doi-asserted-by":"publisher","first-page":"1972","DOI":"10.1002\/hep.23527","volume":"51","author":"MS Ascha","year":"2010","unstructured":"Ascha MS, Hanouneh IA, Lopez R, Tamimi TAR, Feldstein AF, Zein NN. The incidence and risk factors of hepatocellular carcinoma in patients with nonalcoholic steatohepatitis. Hepatology 2010;51:1972\u20131978. https:\/\/doi.org\/10.1002\/hep.23527.","journal-title":"Hepatology"},{"key":"8912_CR80","doi-asserted-by":"publisher","first-page":"597","DOI":"10.1016\/j.cgh.2015.11.019","volume":"14","author":"Y Kawamura","year":"2016","unstructured":"Kawamura Y, Arase Y, Ikeda K et al. Effects of alcohol consumption on hepatocarcinogenesis in Japanese patients with fatty liver disease. Clinical Gastroenterology and Hepatology 2016;14:597\u2013605. https:\/\/doi.org\/10.1016\/j.cgh.2015.11.019.","journal-title":"Clinical Gastroenterology and Hepatology"},{"key":"8912_CR81","doi-asserted-by":"publisher","first-page":"1440","DOI":"10.3748\/wjg.v24.i13.1440","volume":"24","author":"T Kimura","year":"2018","unstructured":"Kimura T, Tanaka N, Fujimori N et al. Mild drinking habit is a risk factor for hepatocarcinogenesis in non-alcoholic fatty liver disease with advanced fibrosis. World Journal of Gastroenterology 2018;24:1440\u20131450. https:\/\/doi.org\/10.3748\/wjg.v24.i13.1440.","journal-title":"World Journal of Gastroenterology"},{"key":"8912_CR82","doi-asserted-by":"publisher","DOI":"10.3390\/jcm13041158","author":"T Miwa","year":"2024","unstructured":"Miwa T, Tajirika S, Inamura N et al. Prevalence of steatotic liver disease based on a new nomenclature in the Japanese population: A health checkup-based cross-sectional study. Journal of Clinical Medicine. 2024. https:\/\/doi.org\/10.3390\/jcm13041158.","journal-title":"Journal of Clinical Medicine"},{"key":"8912_CR83","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2022.11.013","author":"A Louvet","year":"2022","unstructured":"Louvet A, Bourcier V, Archambeaud I et al. Low alcohol consumption influences outcomes in individuals with alcohol-related compensated cirrhosis in a French multicenter cohort. Journal of Hepatology. 2022. https:\/\/doi.org\/10.1016\/j.jhep.2022.11.013.","journal-title":"Journal of Hepatology"},{"key":"8912_CR84","unstructured":"National Health Service. (n.d.). Calculating alcohol units. NHS. (2024) Retrieved from https:\/\/www.nhs.uk\/live-well\/alcohol-advice\/calculating-alcohol-units\/"},{"key":"8912_CR85","unstructured":"National Institute on Alcohol Abuse and Alcoholism. (2018). What is a standard drink? Retrieved from https:\/\/www.niaaa.nih.gov\/alcohols-effects-health\/overview-alcohol-consumption\/what-standard-drink"},{"key":"8912_CR86","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1001\/archinte.158.16.1789","volume":"158","author":"K Bush","year":"1998","unstructured":"Bush K, Kivlahan DR, McDonell MB, Fihn SD, Bradley KA. The AUDIT alcohol consumption questions (AUDIT-C): An effective brief screening test for problem drinking. Archives of Internal Medicine. 1998;158:1789\u20131795. https:\/\/doi.org\/10.1001\/archinte.158.16.1789.","journal-title":"Archives of Internal Medicine."},{"key":"8912_CR87","doi-asserted-by":"publisher","first-page":"918","DOI":"10.1016\/j.jhep.2022.04.040","volume":"77","author":"K Staufer","year":"2022","unstructured":"Staufer K, Huber-Schonauer U, Srebinger G et al. Ethyl glucuronide in hair detects a high rate of harmful alcohol consumption in presumed non-alcoholic fatty liver disease. Journal of Hepatology 2022;77:918\u2013930. https:\/\/doi.org\/10.1016\/j.jhep.2022.04.040.","journal-title":"Journal of Hepatology"},{"key":"8912_CR88","doi-asserted-by":"publisher","DOI":"10.7326\/M23-0518","author":"B Lee","year":"2023","unstructured":"Lee B, Dodge J, Mack W, Leventhal A, Terrault N. National trends in alcohol use, metabolic syndrome, and liver disease from 1999 to 2018. Annals of Internal Medicine. 2023. https:\/\/doi.org\/10.7326\/M23-0518.","journal-title":"Annals of Internal Medicine"},{"key":"8912_CR89","doi-asserted-by":"publisher","first-page":"610","DOI":"10.1016\/j.jhep.2016.11.011","volume":"66","author":"C Lackner","year":"2017","unstructured":"Lackner C, Spindelboeck W, Haybaeck J et al. Histological parameters and alcohol abstinence determine long-term prognosis in patients with alcoholic liver disease. Journal of Hepatology 2017;66:610\u2013618. https:\/\/doi.org\/10.1016\/j.jhep.2016.11.011.","journal-title":"Journal of Hepatology"},{"key":"8912_CR90","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0143293","volume":"10","author":"C Bernsmeier","year":"2015","unstructured":"Bernsmeier C, Weisskopf DM, Pflueger MO et al. Sleep disruption and daytime sleepiness correlating with disease severity and insulin resistance in non-alcoholic fatty liver disease: A comparison with healthy controls. PLOS ONE 2015;10:1\u201316. https:\/\/doi.org\/10.1371\/journal.pone.0143293.","journal-title":"PLOS ONE"},{"key":"8912_CR91","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41387-024-00261-x","volume":"14","author":"J Huang","year":"2024","unstructured":"Huang J, Wu Y, Zheng J, Wang M, Goh GBB, Lin S. The prognostic role of diet quality in patients with MAFLD and physical activity: Data from NHANES. Nutritional Diabetes 2024;14:1\u20137. https:\/\/doi.org\/10.1038\/s41387-024-00261-x.","journal-title":"Nutritional Diabetes"},{"key":"8912_CR92","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000","author":"S Harrison","year":"2024","unstructured":"Harrison S, Bedossa P, Guy C et al. A phase 3, randomized, controlled trial of resmetirom in NASH with liver fibrosis. New England Journal of Medicine. 2024. https:\/\/doi.org\/10.1056\/NEJMoa2309000.","journal-title":"New England Journal of Medicine"},{"key":"8912_CR93","doi-asserted-by":"publisher","first-page":"1113","DOI":"10.1056\/NEJMoa2028395","volume":"384","author":"PN Newsome","year":"2021","unstructured":"Newsome PN, Buchholtz K, NN9931-4296 Investigators et al. A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis. The New England journal of medicine 2021;384:1113\u20131124. https:\/\/doi.org\/10.1056\/NEJMoa2028395.","journal-title":"The New England journal of medicine"},{"key":"8912_CR94","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1056\/NEJMoa2401943","volume":"391","author":"R Loomba","year":"2024","unstructured":"Loomba R, Hartman ML, SYNERGY-NASH Investigators et al. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. The New England Journal of Medicine 2024;391:299\u2013310. https:\/\/doi.org\/10.1056\/NEJMoa2401943.","journal-title":"The New England Journal of Medicine"},{"key":"8912_CR95","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1056\/NEJMoa2304286","volume":"389","author":"R Loomba","year":"2023","unstructured":"Loomba R, Sanyal AJ, Kowdley KV et al. Randomized, Controlled Trial of the FGF21 Analogue Pegozafermin in NASH. The New England Journal of Medicine 2023;389:998\u20131008. https:\/\/doi.org\/10.1056\/NEJMoa2304286.","journal-title":"The New England Journal of Medicine"},{"key":"8912_CR96","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1056\/NEJMoa2401755","volume":"391","author":"AJ Sanyal","year":"2024","unstructured":"Sanyal AJ, Bedossa P, 1404\u20130043 Trial Investigators et al. A Phase 2 Randomized Trial of Survodutide in MASH and Fibrosis. The New England Journal of Medicine 2024;391:311\u2013319. https:\/\/doi.org\/10.1056\/NEJMoa2401755.","journal-title":"The New England Journal of Medicine"},{"key":"8912_CR97","doi-asserted-by":"publisher","first-page":"731","DOI":"10.4254\/wjh.v16.i5.731","volume":"16","author":"C Xie","year":"2024","unstructured":"Xie C, Alkhouri N, Elfeki MA. Role of incretins and glucagon receptor agonists in metabolic dysfunction-associated steatotic liver disease: Opportunities and challenges. World Journal of Hepatology 2024;16:731\u2013750. https:\/\/doi.org\/10.4254\/wjh.v16.i5.731.","journal-title":"World Journal of Hepatology"},{"key":"8912_CR98","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1172\/jci.insight.170671","volume":"8","author":"V Chuong","year":"2023","unstructured":"Chuong V, Farokhnia M, Khom S et al. The glucagon-like peptide-1 (GLP-1) analogue semaglutide reduces alcohol drinking and modulates central GABA neurotransmission. JCI Insight 2023;8:1\u201316. https:\/\/doi.org\/10.1172\/jci.insight.170671.","journal-title":"JCI Insight"},{"key":"8912_CR99","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41598-023-48267-2","volume":"13","author":"F Quddos","year":"2023","unstructured":"Quddos F, Hubshman Z, Tegge A et al. Semaglutide and Tirzepatide reduce alcohol consumption in individuals with obesity. Scientific Reports 2023;13:1\u201312. https:\/\/doi.org\/10.1038\/s41598-023-48267-2.","journal-title":"Scientific Reports"},{"key":"8912_CR100","doi-asserted-by":"publisher","DOI":"10.1016\/j.soard.2017.03.021","author":"W King","year":"2017","unstructured":"King W, Chen J-Y, Courcoulas A et al. Alcohol and other substance use after bariatric surgery: Prospective evidence from a US multicenter cohort study. Surgical Obesity and Related Diseases. 2017. https:\/\/doi.org\/10.1016\/j.soard.2017.03.021.","journal-title":"Surgical Obesity and Related Diseases"},{"key":"8912_CR101","doi-asserted-by":"publisher","DOI":"10.1111\/acer.12805","author":"C Spadola","year":"2015","unstructured":"Spadola C, Wagner E, Dillon F, Trepka M, de la Cruz-Mu\u00f1oz N, Messiah S. Alcohol and drug use among postoperative bariatric patients: A systematic review of the emerging research and its implications. Alcohol Clin Exp Res. 2015. https:\/\/doi.org\/10.1111\/acer.12805.","journal-title":"Alcohol Clin Exp Res"},{"key":"8912_CR102","doi-asserted-by":"publisher","first-page":"2516","DOI":"10.1001\/jama.2012.6147","volume":"307","author":"WC King","year":"2012","unstructured":"King WC, Chen JY, Mitchell JE et al. Prevalence of alcohol use disorders before and after bariatric surgery. JAMA 2012;307:2516\u20132525. https:\/\/doi.org\/10.1001\/jama.2012.6147.","journal-title":"JAMA"}],"container-title":["Digestive Diseases and Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10620-025-08912-4\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10620-025-08912-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,30]],"date-time":"2025-05-30T05:04:14Z","timestamp":1748581454000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10620-025-08912-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,3,1]]},"references-count":102,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["8912"],"URL":"https:\/\/doi.org\/10.1007\/s10620-025-08912-4","relation":{},"ISSN":["0163-2116","1573-2568"],"issn-type":[{"value":"0163-2116","type":"print"},{"value":"1573-2568","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,3,1]]},"assertion":[{"value":"23 July 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 February 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 March 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"HCP\u2013Lectures and advisory board fees from Orphalan, Novo Nordisk, EISAI and Advanz Pharm.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}}]}}